U.S. Department of Health and Human Services (HHS)
Parent: UC Comment Letters
eScholarship stats: Breakdown by Item for July through October, 2026
| Item | Title | Total requests | Download | View-only | %Dnld |
|---|---|---|---|---|---|
| 9st228b4 | UC Response to NIH Pause on New Submissions to the NIH Human Embryonic Stem Cell Registry and Request for Information on Reducing Reliance on Human Embryonic Stem Cells in NIH-Supported Research (NOT-OD-26-031) | 126 | 8 | 118 | 6.3% |
| 442553qv | UC Comments on NIH's Request for Information on Proposed Changes to Reporting Outcomes from NIH Peer Review | 77 | 34 | 43 | 44.2% |
| 9vw6z5h0 | UC Comments on NIH/OLAW's RFI on Update to NOT-OD-05-034 Guidance on Prompt Reporting of Noncompliances to OLAW (NOT-OD-23-063) | 71 | 5 | 66 | 7.0% |
| 7br0n9jb | UC Comments in Response to NOT-OD-23-034, "Request for Information (RFI) on Proposed Simplified Review Framework for NIH Research Project Grant Application" | 54 | 9 | 45 | 16.7% |
| 9vd827xq | UC Comments on Draft OHRP Guidance on Use of a Single Institutional Review Board for Cooperative Research (Docket ID Number HHS-OASH-2022-0011, July 1, 2022) | 46 | 6 | 40 | 13.0% |
| 99n0x1kk | UC Comments on NIH/OLAW's RFI on Proposed Guidance to Assured Insitutions on Cephalopod Care and Use (NOT-OD-23-176) | 43 | 6 | 37 | 14.0% |
| 0gr9367z | UC Comments in Response to the NIH Request for Information: Developing Consent Language for Future Use of Data and Biospecimens (NOT-OD-21-131) | 42 | 12 | 30 | 28.6% |
| 19t30344 | University of California Response to NIH Request for Information on Maximizing Research Funds by Limiting Allowable Publishing Costs (NOT-OD-25-138) | 41 | 5 | 36 | 12.2% |
| 9sn6m48b | UC Comments on FDA's Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products; Draft Guidance for Industry; Availability (Docket No. FDA-2021-D-1214, December 9, 2021) | 40 | 6 | 34 | 15.0% |
| 3591b3jz | UC Comments on FDA Guidance Document: Investigator Responsibilities – Safety Reporting for Investigational Drugs and Devices (FDA-2021-D-0368) | 37 | 5 | 32 | 13.5% |
| 4rw9g2k6 | University of California Response to NIH Request for Information on Draft NIHControlled-Access Data Policy and Proposed Revisions to NIH Genomic Data Sharing Policy(NOT-OD-26-023) | 37 | 4 | 33 | 10.8% |
| 7v11n0rm | UC Comments on FDA Docket No. FDA-2019-N-2175 for “Institutional Review Boards; Cooperative Research.” (September 28, 2022) | 36 | 8 | 28 | 22.2% |
| 06g5v1tp | UC Comments in Response to 2024-16496 (89 FR 60985) & 2024-22146 (89 FR 78835), End-Use and End-User Based Export Controls, Including U.S. Persons Activities Controls: Military and Intelligence End Use and End Users (July 29, 2024), RIN 0694-AJ43 | 35 | 4 | 31 | 11.4% |
| 8m65c5h9 | UC Comments in Response to NOT-OD-21-018, “Request for Information (RFI):Inviting Comments and Suggestions on the NIH-Wide Strategic Plan for COVID-19 Research” | 35 | 3 | 32 | 8.6% |
| 3pm6d220 | UC Response to Comment Request on NIH Electronic Application System for NIH Certificates of Confidentiality (CoC) [90 FR 30652] | 34 | 4 | 30 | 11.8% |
| 637846c7 | UC Comments in Response to NIH's RFI on the NIH Draft Public Access Policy | 34 | 4 | 30 | 11.8% |
| 7sz8s1zc | UC Comments in Response to the Request for Information on Proposed Updates and Long-Term Considerations for the NIH Genomic Data Sharing Policy (NOT-OD-22-029) | 33 | 5 | 28 | 15.2% |
| 6bk2s9gf | UC Comments NIH's RFI on Developing Consent Language for Research Using Digital Health Technologies (NOT-OD-24-002) | 32 | 4 | 28 | 12.5% |
| 8nj635p3 | UC Comments in Response to the NIH Request for Public Comments on DRAFT Supplemental Information to the NIH Policy for Data Management and Sharing: Protecting Privacy When Sharing Human Research Participant Data (NOT-OD-22-131) | 32 | 7 | 25 | 21.9% |
| 28j9736p | UC Request for Extension to Comment Period: Docket No. FDA-2019-N-2175 for “Institutional Review Boards; Cooperative Research.” (September 28, 2022) | 31 | 5 | 26 | 16.1% |
| 0r54j9xv | UC Comments in Response to NOT-AT-22-026, “Request for Information (RFI): Investigators’ Interests in and Barriers to Research Studies on the Health Effects of Cannabis and its Constituents” | 30 | 5 | 25 | 16.7% |
| 5wd6c2xg | UC Comments in Response to NIH/OLAW's RFI on Clarification of Animal Activities Exempt from the PHS Policy Requirements for IACUC Review (NOT-OD-23-119) | 30 | 5 | 25 | 16.7% |
| 9h75q200 | UC Comments on Docket No. FDA-2021-N-0286 for “Protection of Human Subjects and Institutional Review Boards” (September 28, 2022) | 30 | 6 | 24 | 20.0% |
| 2ng1337v | UC Response to HHS Notice of Committee Establishment, Notice of Intent To Convene, and Call for Nominations for the NIH Human Fetal Tissue Research Ethics Advisory Board for Fiscal Year 2020 | 29 | 4 | 25 | 13.8% |
| 6vx692vq | UC Comments on Certificates of Confidentiality; Draft Guidance for Sponsors, Sponsor-Investigators, Researchers, Industry, and Food and Drug Administration Staff: Availability (FDA-2019-D-3592) | 29 | 5 | 24 | 17.2% |
| 0p60d992 | UC Comments on FDA Final Order regarding Designating Additions to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Acton [FDA-2008-N-0567-0055] | 27 | 2 | 25 | 7.4% |
| 5ng1c3d5 | UC Comments on NIH's Framework for Discussion, dates June 2024, Seeking Input on Reforming the NIH | 26 | 6 | 20 | 23.1% |
| 5t52r4mg | UC Comments in Response to NOT-OD-26-112 "Request for Comment: Draft NIH Biosafety Policy for Research Involving Biohazards" | 25 | 6 | 19 | 24.0% |
| 4p55d0x9 | UC Comments on the FDA-NIH Resource on Terminology for Clinical Research | 24 | 4 | 20 | 16.7% |
| 8z99q8c0 | UC Request to FDA to Extend Comment Period for Docket No. FDA-2021-N-0286 for “Protection of Human Subjects and Institutional Review Boards” (September 28, 2022) | 24 | 4 | 20 | 16.7% |
| 93x6z1b4 | UC Comments in Response to NOT-OD-23-091, "Request for Information on the NIH Plan to Enhance Public Access to the Results of NIH-Supported Research" | 24 | 5 | 19 | 20.8% |
| 9mf9j9bq | UC Comments in Response to FDA's Proposed Guidance for Sponsors, Investigators,and Institutional Review Boards on Key Information and Facilitating Understanding in Informed Consent (Docket Number: FDA-2022-D-2997) | 24 | 3 | 21 | 12.5% |
| 4fb874mt | UC Comments in Response to the HHS Regulations RFI, “Request for Information and Comments on the 2005 Public Health Service Policies on Research Misconduct” | 21 | 3 | 18 | 14.3% |
| 5wz509zr | UC Comments in Response to NOT-OD-20-013, “Request for Public Comments on a DRAFT NIH Policy for Data Management and Sharing and Supplemental DRAFT Guidance” | 20 | 2 | 18 | 10.0% |
| 3rs8v26w | UC Letter Regarding Gender Diversity and Inclusion on the OHRP IRB Registration Form | 19 | 2 | 17 | 10.5% |
| 2db6h4gd | UC Comments in Response to Request for Information (RFI) on Flexibilities for Streamlining IACUC Review of Protocols and Significant Changes (NOT-OD-23-152) | 17 | 3 | 14 | 17.6% |
| 5dr3q55j | UC Comments on Draft NIH Policy on Sharing Summary Level Study Results with Clinical Research Participants (NOT-OD-26-113) | 9 | 1 | 8 | 11.1% |
Note: Due to the evolving nature of web traffic, the data presented here should be considered approximate and subject to revision. Learn more.